Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study)
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F44555601%3A13450%2F17%3A43894521" target="_blank" >RIV/44555601:13450/17:43894521 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/17:00098742 RIV/00216208:11110/17:10359496 RIV/00216208:11120/17:43912579 RIV/00216208:11140/17:10359496 and 9 more
Result on the web
<a href="https://ac.els-cdn.com/S0002870316302150/1-s2.0-S0002870316302150-main.pdf?_tid=5c31c781-9385-47ef-b717-e4c134e1eae5&acdnat=1551950439_3ecf31f47d33e5b2c4f9c99e47bbd897" target="_blank" >https://ac.els-cdn.com/S0002870316302150/1-s2.0-S0002870316302150-main.pdf?_tid=5c31c781-9385-47ef-b717-e4c134e1eae5&acdnat=1551950439_3ecf31f47d33e5b2c4f9c99e47bbd897</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ahj.2016.10.003" target="_blank" >10.1016/j.ahj.2016.10.003</a>
Alternative languages
Result language
angličtina
Original language name
Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study)
Original language description
Background Atrial fibrillation (AF), with a prevalence of 1% to 2%, is the most common cardiac arrhythmia. Without antithrombotic treatment, the annual risk of a cardioembolic event is 5% to 6%. The source of a cardioembolic event is a thrombus, which is usually formed in the left atrial appendage (LAA). Prevention of cardioembolic events involves treatment with anticoagulant drugs: either vitamin K antagonists or, recently, novel oral anticoagulants (NOAC). The other (nonpharmacologic) option for the prevention of a cardioembolic event involves interventional occlusion of the LAA. Objective To determine whether percutaneous LAA occlusion is noninferior to treatment with NOAC in AF patients indicated for long-term systemic anticoagulation. Study design The trial will be a prospective, multicenter, randomized noninferiority trial comparing 2 treatment strategies in moderate to high-risk AF patients (ie, patients with history of significant bleeding, or history of cardiovascular event(s), or a with CHA(2)DS(2)VASc >= 3 and HAS-BLED score >= 2). Patients will be randomized into a percutaneous LAA occlusion (group A) or a NOAC treatment (group B) in a 1: 1 ratio; the randomization was done using Web-based randomization software. A total of 396 study participants (198 patients in each group) will be enrolled in the study. The primary end point will be the occurrence of any of the following events within 24 months after randomization: stroke or transient ischemic attack (any type), systemic cardioembolic event, clinically significant bleeding, cardiovascular death, or a significant periprocedural or device-related complications. Conclusion The PRAGUE-17 trial will determine if LAA occlusion is noninferior to treatment with NOAC in moderate-to high-risk AF patients.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
AMERICAN HEART JOURNAL
ISSN
0002-8703
e-ISSN
—
Volume of the periodical
neuveden
Issue of the periodical within the volume
183
Country of publishing house
US - UNITED STATES
Number of pages
7
Pages from-to
108-114
UT code for WoS article
000390259600015
EID of the result in the Scopus database
2-s2.0-85006765794